Intraocular pressure rise is predictive of vision improvement after intravitreal triamcinolone acetonide for diabetic macular oedema: a retrospective analysis of data from a randomised controlled trial

Roderick F O'Day, Daniel Barthelmes, Meidong Zhu, Tien Y Wong, Ian L McAllister, Jennifer J Arnold, Mark C Gillies, Roderick F O'Day, Daniel Barthelmes, Meidong Zhu, Tien Y Wong, Ian L McAllister, Jennifer J Arnold, Mark C Gillies

Abstract

Background: Intravitreal triamcinolone acetonide (IVTA) is an effective treatment for recalcitrant diabetic macular oedema (DMO). It has been shown to improve vision with benefits persisting up to five years. The most common initial side effect of IVTA treatment is rise in intraocular pressure, occurring in approximately 50% of patients within the first 6 months of treatment. We evaluated whether there is a correlation between the development of intraocular pressure rise and improvement in vision.

Methods: Analysis of individual data from 33 eyes of 33 participants treated with IVTA for DMO from a prospective, randomised, double-masked, placebo controlled trial. The degree of intraocular pressure (IOP) rise was correlated with improvement in best-corrected visual acuity (BCVA) at 1 and 6 months.

Results: The proportion of eyes gaining 5 or more logMAR letters was higher in eyes with greater IOP rise (p = 0.044). Better absolute improvement in BCVA at 6 months (p = 0.045) was also found in eyes with greater IOP rise. Regression analyses revealed a correlation between IOP rise of 10 or more mmHg and absolute BCVA improvement at 6 months (odds ratio 1.22, 95% confidence interval 1.01-1.48, p = 0.039), but not at 1 month.

Conclusions: IOP rise and vision improvement appear to be correlated following IVTA for DMO, suggesting that the mechanisms that cause both may be linked.

Trial registration: Clinical trials.gov NCT00167518, September 5, 2005.

References

    1. Kohner E. Diabetic retinopathy. Clin Endocrinol Metab. 1977;6:345–375. doi: 10.1016/S0300-595X(77)80042-X.
    1. Giuliari GP. Diabetic retinopathy: current and new treatment options. Curr Diabetes Rev. 2012;8:32–41. doi: 10.2174/157339912798829188.
    1. Schmucker C, Loke YK, Ehlken C, Agostini HT, Hansen LL, Antes G, Lelgemann M. Intravitreal becavizumab (Avastin) versus ranibuzumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Br J Ophthalmol. 2011;95:308–317. doi: 10.1136/bjo.2009.178574.
    1. Quaggin SE. J Clin Invest. 2012. Turning a blind eye to anti-VEGF toxicities.
    1. van Wijngararden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA. 2005;293:1509–1513. doi: 10.1001/jama.293.12.1509.
    1. Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology. 2004;111:2044–2049. doi: 10.1016/j.ophtha.2004.05.025.
    1. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular oedema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006;113:1533–1538. doi: 10.1016/j.ophtha.2006.02.065.
    1. Gillies MC, Simpson JM, Gaston C, Hunt G, Ali H, Zhu M, Sutter F. Five-year results of a randomized clinical trial with open label extension of intravitreal triamcinolone for refractory diabetic macular oedema. Ophthalmology. 2009;116:2182–2187. doi: 10.1016/j.ophtha.2009.04.049.
    1. Gillies MC, McAllister IL, Zhu M, Wong W, Louis D, Arnold JJ, Wong TY. Pretreatment with intravitreal triamcinolone before laser for diabetic macular oedema: 6-month results of a randomized, placebo-controlled trial. Invest Ophthalmol Vis Sci. 2010;51:2322–2328. doi: 10.1167/iovs.09-4400.
    1. Jonas JB, Kamppeter BA, Harder B, Vosmmerbaeumer U, Sauder G, Spandau UH. Intravitreal triamcinolone acetonide for diabetic macular oedema: a prospective, randomized study. J Ocul Phamacol Ther. 2006;22:200–207. doi: 10.1089/jop.2006.22.200.
    1. Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R, Caulin C, Gaudric A. Intravitreal triamcinolone acetonide for diabetic diffuse macular oedema: Preliminary results of a prospective controlled trial. Ophthalmology. 2004;111:218–224. doi: 10.1016/j.ophtha.2003.05.037.
    1. Diabetic Retinopathy Clinical Research Network Ophthalmology A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular oedema. Ophthalmology. 2008;115:1447–1459. doi: 10.1016/j.ophtha.2008.06.015.
    1. Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, Mitchell P, Zhu M, Hunyor AB. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol. 2004;122:336–340. doi: 10.1001/archopht.122.3.336.
    1. Konstantopoulos A, Williams CP, Newsom RS, Luff AJ. Ocular morbidity associated with intravitreal triamcinolone acetonide. Eye (Lond) 2007;21:317–320. doi: 10.1038/sj.eye.6702416.
    1. Gillies MC, Kuzniarz M, Craig J, Ball M, Luo W, Simpson J. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology. 2005;112:139–143. doi: 10.1016/j.ophtha.2004.07.017.
    1. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology. 2005;112:593–598. doi: 10.1016/j.ophtha.2004.10.042.
    1. Chae JB, Joe SG, Yang SJ, Lee JY, Kim J-G, Yoon TH. An increase in intraocular pressure after intravitreal steroid injection facilitates reduce of macular edema. Eye (Lond) 2012;26:479–480. doi: 10.1038/eye.2011.310.
    1. Sonmez K, Ozturk F. Complications of intravitreal triamcinolone acetonide for macular edema and predictive factors for intraocular pressure elevation. Int J Ophthalmol. 2012;5:719–725.
    1. Jonas J, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Opthalmol. 2003;87:24–27. doi: 10.1136/bjo.87.1.24.
    1. Hernandez MR, Wenk EJ, Weinstein BI, Abumohor P, Podos SM, Dunn MW, Southren AL. Glucocorticoid target cells in human outflow pathway: autopsy and surgical specimens. Invest Ophthalmol Vis Sci. 1983;24:1612–1616.
    1. Weinreb RN, Bloom E, Baxter JD, Alvarado J, Lan N, O’Donnell J, Polansky JR. Detection of glucocorticoid receptors in cultured human trabecular cells. Invest Ophthalmol Vis Sci. 1981;21:403–407.
    1. Vijayasekaran S, McAllister IL, Morgan WH, Mendis KR, McMenamin PG, Cringle SJ, Yu DY. Intravitreal triamcinolone acetonide induced changes in the anterior segment in a pig model of branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2011;249:215–222. doi: 10.1007/s00417-010-1458-y.
    1. Becker B, Mills DW. Corticosteroids and intraocular pressure. Arch Ophthalmol. 1963;70:500–507. doi: 10.1001/archopht.1963.00960050502012.
    1. Johnson DH, Bradley JM, Ascott TS. The effect of dexamethasone on glycosaminoglycans of human trabecular meshwork in the perfusion organ culture. Invest Ophthalmol Vis Sci. 1990;31:2568–2571.
    1. Larsson J, Zhu M, Sutter F, Gillies MC. Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone. Am J Ophthalmol. 2005;139:802–806. doi: 10.1016/j.ajo.2004.12.054.
    1. Tretiach M, Madigan MC, Wen L, Gillies MC. Effect of muller cell co-culture on in vitro permeability of bovine retinal vascular endothelium in normoxic and hypoxic conditions. Neurosci Lett. 2005;378:160–165. doi: 10.1016/j.neulet.2004.12.026.
    1. Wenzel A, Grimm C, Seeliger MW, Jaissle G, Hafezi F, Kretschmer R, Zrenner E, Remé CE. Prevention of photoreceptor apoptosis by activation of the glucocorticoid receptor. Invest Ophthalmol Vis Sci. 2001;42:1653–1659.
    1. Edelman JL. Differentiating intraocular glucocorticoids. Ophthalmologica. 2010;224:25–30. doi: 10.1159/000315158.
    1. Shin HJ, Lee SH, Chung H, Kim HC. Association between photoreceptor integrity and visual outcome in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2012;250:61–70. doi: 10.1007/s00417-011-1774-x.
    1. James ER, Robertson L, Ehlert E, Fitzgerald P, Droin N, Green DR. Presence of a transcriptionally active glucocorticoid receptor α in lens epithelial cells. Invest Ophthalmol Vis Sci. 2003;44:5269–5276. doi: 10.1167/iovs.03-0401.
Pre-publication history
    1. The pre-publication history for this paper can be accessed here:

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться